Ocular Toxicities in Patients With Cancer: Multidisciplinary Perspectives

1.25 CME
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ocular Toxicities in Patients With Cancer: Multidisciplinary Perspectives


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This educational activity is supported by an educational grant from GlaxoSmithKline.

Activity Description

The refinement of chemotherapy regimens and development of molecular-targeted agents have significantly improved clinical outcomes for patients with cancer. Although these therapeutic regimens provide effective therapy, some have been associated with ocular adverse events. In clinical studies evaluating antibody-drug conjugates (ADCs) that target B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma (MM), corneal toxicities were reported. However, most adverse events were manageable. For the optimal integration of these agents into treatment protocols, it is imperative that ophthalmologists and oncologists are aware of these adverse events so that timely and appropriate management can be initiated. In this CME activity, a multidisciplinary team of experts examine ocular toxicities associated with ADCs in cancer therapy along with the underlying molecular mechanisms; evaluate the latest clinical evidence regarding ocular toxicities associated with BCMA-targeted antibody therapies in the management of patients with relapsed or refractory MM; and provide effective multidisciplinary strategies for the recognition, mitigation, and management of ocular toxicities in patients undergoing therapy for cancer.

Target Audience

The intended audience for this activity is ophthalmologists, optometrists, hematologist-oncologists, and other health care professionals involved in the management of patients with relapsed/refractory multiple myeloma.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Examine the ocular toxicities associated with ADCs for cancer therapy as well as the latest understanding of their underlying molecular mechanisms.
  • Evaluate the latest clinical evidence regarding the ocular toxicities associated with BCMA-targeted antibody drug conjugates for the management of patients with relapsed or refractory MM.
  • Summarize effective multidisciplinary strategies, including patient education, for the recognition, mitigation, and management of ocular toxicities in patients undergoing anti-cancer therapy.

Activity Chair

Sagar Lonial, MD, FACP
Professor and Executive Vice Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, GA        


Asim V. Farooq, MD
Associate Professor
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science University of Chicago Medical Center
Chicago, IL

Shaily D. Shah, MD, FAAO, FASCRS
Northern California Cornea Associates, Inc.,
Walnut Creek, CA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Medical Writer

Valerie Zimmerman, PhD


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, November 25, 2021, to November 25, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Lonial, Farooq, and Shah during a virtual expert panel discussion held on August 7, 2021. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Activity Chair and Faculty report the following relationship(s)

Asim V. Farooq, MD
Consultant: GlaxoSmithKline, Five Prime Therapeutics

Sagar Lonial, MD, FACP
Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Takeda
Independent Research Contractor: Bristol-Myers Squibb, Janssen, Takeda
Individual Stocks and Stock Options: TG Therapeutics
Board of Directors: TG Therapeutics

Shaily D. Shah, MD, FAAO, FASCRS
Speakers Bureau: GlaxoSmithKline

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Medical Writer reports the following relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com